The phrase "accessibility using" is correct and usable in written English.
It can be used when discussing methods or tools that enhance or facilitate accessibility in various contexts, such as technology, design, or services.
Example: "We are focusing on improving accessibility using innovative software solutions that cater to diverse user needs."
Alternatives: "accessibility through" or "accessibility via".
Human fetal astrocytes (n = 2) and iPSC-derived astrocytes (n = 4) were profiled for chromatin accessibility using the assay for transposase-accessible chromatin ATAC-seq 11,26 ATAC-seq 11,26
Measuring physical accessibility using GIS could help assess the distribution of and access to general healthcare delivery.
GP premises accessibility was compared with community pharmacy accessibility using previously reported data, 11 and shows for GP premises, access is lower than community pharmacies across all deprivation deciles, but particularly in the least deprived areas (figure 3).
Despite differences in legislation between Canada and Australia, accessibility using travel time of one hour has become an accepted measure of access particularly in an emergency [ 17, 22, 24, 34].
For this, we profiled chromatin accessibility using ATAC-seq.
We also examined in vivo accessibility using cellular expression of a prokaryotic methylase.
Living and working within the same compound wall is depicted vividly as a "spatial bond" [34]; thus, the job accessibility used to be pretty high in the planned economy era.
The measure of accessibility used is the fraction of structures in which a nucleotide is found in a single-stranded conformation, when all optimal and suboptimal structures predicted are considered.
The activeICM method is able to represent three-dimensional documents, such as iSee datapacks, in a manner independent of hardware and operating system and web-accessibility using only freely-available components.
Positioning activity was also monitored by restriction endonuclease accessibilities using Hae III and Msp I as detailed previously [36], [37].
Then, surface residues in antibody variable (Fv) domains (light chain and heavy chain variable domains (Vl + Vh)) of these selected antibodies were determined by calculation of residue solvent accessibilities using software Swiss-PdbViewer [35].
